Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rezvilutamide Monotherapy as Adjuvant Treatment for High-Risk Prostate Cancer Post-Prostatectomy
NCT07711314Phase 2Recruiting
- Sponsor
- Nanjing Drum-Tower Hospital
- Start
- Jul 2026
- Primary completion
- May 2027
- Countries
- 1
01
Overview
A Phase 2 trial of rezvilutamide in prostate cancer (PCa), sponsored by Nanjing Drum-Tower Hospital. Started Jul 2026; status: recruiting.
02
Drugs
rezvilutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT07711314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07711314.